BioSciences entered a sponsored research agreement with Ted M. Ross, Ph.D., an assistant professor at the University of Pittsburgh
's Center for Vaccine Research. Dr. Ross will explore the use of the company’s lead influenza
product, Viprovex, which is at the preclinical stage, as an adjuvant to novel influenza vaccines.
ImmuneRegen is already developing the compound for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. Viprovex is a derivative of Homspera, which is in advanced preclinical testing as a stem cell stimulant to help wound healing.
Previous studies performed at other research facilities revealed Viprovex used as a vaccine adjuvant increased concentrations in blood of antibodies against both the virus used for vaccination as well as cross-reactive antibodies against different influenza strains, according to the company.